Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 28;12:849376. doi: 10.3389/fonc.2022.849376

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Jawad, Afkhami, Ding, Zhang, Li, Young, Xu, Cui, Zhao, Halene, Al-Kali, Viswanatha, Chen, He and Zheng

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

DNMT3A R882 mutations confer increased risk of AML transformation and worse progression free survival in MDS, which are masked by the coexisting SF3B1 or SRSF2 mutations. (A) Cumulative incidence of AML transformation in DNMT3A (R882 vs. Non-R882) mutant MDS. (B) Progression free survival analysis in patients with DNMT3A (R882 vs. Non-R882) mutant myelodysplastic syndrome (MDS). (C) The distribution of IPSS-R scores in the R882 group and the other group. (D) Cox proportional hazards model analysis of risk factors for worse progression free survival. Statistically significant factors are highlighted with black lines. (E) Overall survival analysis in patients with DNMT3A (R882 vs. Non-R882) mutant myelodysplastic syndrome (MDS). (F) Progression free survival analysis in DNMT3A (R882 vs. Non-R882) mutant MDS with mutant and wildtype SF3B1/SRSF2.